Zest Is Back At Zealand With Cash Injection And A Clinical Win

Turning Corner After A Tough Year

 
• By Kevin Grogan

The Danish biotech is looking to end 2022 on a high after raising over $105m and posting positive Phase III data on glepaglutide.

mermaid
Things are looking up for the Copenhagen-headquartered firm • Source: Alamy

More from Financing

More from Business